CGEN - コンピュジェン (Compugen Ltd.) コンピュジェン

 CGENのチャート


 CGENの企業情報

symbol CGEN
会社名 Compugen Ltd (コンピュジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンピュジェン(Compugen Ltd.)は治療薬の発見会社で、免疫学と腫瘍学分野での満たされていない重要なニーズに対応する治療用タンパク質及びモノクローナル抗体を中心とする。同社は主に発見された製品候補のさらなる開発・商業化及び各種形態の研究・発見契約を含む提携を行う。同社のプログラムパイプラインは検証から前臨床試験に至るまで様々な段階における30種類以上の治療薬候補で構成される。パイプラインプログラムの下で、新たに発見された分子はシリコン内での予測と選択の直後での実験的評価を開始する時にプログラムに入る。パイプラインプログラムは追加の18ヶ月間以下の特定分子向けの様々な前臨床活動が続く動物疾患モデルや重複実験を含む生体内及び生体内の実験的検証で構成される。   コンピュジェンはイスラエルの製薬会社。モノクロ―ナル抗体および腫瘍学および免疫学の分野の治療用タンパク質に焦点を当て薬剤の開発を行う。同社は、伝統的な実験に基づく薬物候補の発見とは異なり、コンピュ―タによって独自の科学的理解および予測プラットフォ―ム、アルゴリズム、機械学習システムを利用し、予測し製品候補の開発を行う。本社はテレアビブ。   Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
本社所在地 Azrieli Center 26 Harokmim Street Building D Holon 5885849 ISR
代表者氏名 Paul Jai Sekhri ポール・ジャイ・セクフリ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-765-8585
設立年月日 34001
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 101人
url www.cgen.com
nasdaq_url https://www.nasdaq.com/symbol/cgen
adr_tso
EBITDA EBITDA(百万ドル) -29.58400
終値(lastsale) 3.36
時価総額(marketcap) 192182017.44
時価総額 時価総額(百万ドル) 194.16020
売上高 売上高(百万ドル) 10.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151.70420
当期純利益 当期純利益(百万ドル) -29.27000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Compugen Ltd. (USA) revenues increased from $0K to $10M. Net loss decreased 44% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.35 to -$0.19.

 CGENのテクニカル分析


 CGENのニュース

   A stock that deserves closer examination: Compugen Ltd. (CGEN)  2022/10/31 15:24:00 US Post News
A share of Compugen Ltd. (NASDAQ:CGEN) closed at $0.88 per share on Friday, up from $0.81 day before. While Compugen Ltd. has overperformed by 7.76%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CGEN fell by -86.52%, with highs and lows ranging from $7.48 to $0.51, […]
   Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022  2022/10/31 11:00:00 PR Newswire
HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022,…
   Compugen Ltd. (CGEN) is an excellent investment, but the stock is overvalued/undervalued right now  2022/10/24 11:24:00 US Post News
The share price of Compugen Ltd. (NASDAQ:CGEN) fell to $0.83 per share on Friday from $0.87. While Compugen Ltd. has underperformed by -4.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CGEN fell by -87.33%, with highs and lows ranging from $7.48 to $0.51, whereas the […]
   Compugen Ltd. (CGEN) Sitting On The Launch Pad, Waiting For Long Term Investors  2022/10/22 14:00:00 Stocks Register
Compugen Ltd. (NASDAQ:CGEN) price on Friday, October 21, fall -4.87% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.83. A look at the stock’s price movement, the close in the last trading session was $0.87, moving within a range at $0.80 and $0.87. The beta value (5-Year … Compugen Ltd. (CGEN) Sitting On The Launch Pad, Waiting For Long Term Investors Read More »
   Compugen Ltd. (NASDAQ: CGEN): Can A Stock Be -79.71% Lower Year-To-Date And Still Be A Loser?  2022/10/21 12:30:00 Marketing Sentinel
Compugen Ltd. (NASDAQ:CGEN)’s traded shares stood at 1.73 million during the last session, with the company’s beta value hitting 2.31. At the close of trading, the stock’s price was $0.87, to imply an increase of 0.97% or $0.01 in intraday trading. The CGEN share’s 52-week high remains $7.48, putting it -759.77% down since that peak … Compugen Ltd. (NASDAQ: CGEN): Can A Stock Be -79.71% Lower Year-To-Date And Still Be A Loser? Read More »
   Earnings Scheduled For May 16, 2022  2022/05/16 09:18:44 Benzinga
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ: ACRX ) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. • Synthetic Biologics (AMEX: SYN ) is likely to report earnings for its first quarter. • Passage Bio (NASDAQ: PASG ) is estimated to report earnings for its first quarter. • Taysha Gene Therapies (NASDAQ: TSHA ) is expected to report earnings for its first quarter. • HOOKIPA Pharma (NASDAQ: HOOK ) is likely to report quarterly loss at $0.24 per share on revenue of $14.53 million. • Sunworks (NASDAQ: SUNW ) is likely to report quarterly loss at $0.26 per share on revenue of $28.70 million. • Data Storage (NASDAQ: DTST ) is estimated to report quarterly earnings at $0.01 per share on revenue of $6.00 million. • 1847 Goedeker (AMEX: GOED ) is projected to report quarterly earnings at $0.04 per share on revenue of $152.35 million. • BIO-key Intl (NASDAQ: BKYI ) is estimated to report quarterly loss at $0.22 per share on revenue of $1.
   Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call Transcript  2022/02/24 17:56:08 Seeking Alpha
   Compugen GAAP EPS of -$0.10 beats by $0.04  2022/02/24 12:06:54 Seeking Alpha
Compugen press release (CGEN): Q4 GAAP EPS of -$0.10 beats by $0.04.As of December 31, 2021, cash, cash related accounts, short-term and long-term bank deposits totaled to…
   Compugen Q4 2021 Earnings Preview  2022/02/23 18:57:31 Seeking Alpha
Compugen (NASDAQ:CGEN) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.13 (-30.0% Y/Y) and the…
   Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022  2022/02/10 12:00:00 PR Newswire
HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February
   Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call Transcript  2022/02/24 17:56:08 Seeking Alpha
   Compugen GAAP EPS of -$0.10 beats by $0.04  2022/02/24 12:06:54 Seeking Alpha
Compugen press release (CGEN): Q4 GAAP EPS of -$0.10 beats by $0.04.As of December 31, 2021, cash, cash related accounts, short-term and long-term bank deposits totaled to…
   Compugen Q4 2021 Earnings Preview  2022/02/23 18:57:31 Seeking Alpha
Compugen (NASDAQ:CGEN) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.13 (-30.0% Y/Y) and the…
   Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022  2022/02/10 12:00:00 PR Newswire
HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February
   Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference  2022/02/09 12:00:00 PR Newswire
HOLON, Israel, Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference (virtual), on…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンピュジェン CGEN Compugen Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)